Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Sonki who wrote (5796)	10/5/1998 8:32:00 PM
From: B.REVERE	Read Replies (1) \| Respond to of 9523

Sonki, Pfe is getting hurt because the world economies are in trouble. Even if pfe makes their quarter,(which I think they will), the stock will get caught in the general market purge. When margin calls get made, people have to raise cash and unfortunately pfe is one of about 15 stocks that have not gotten killed this year. There is nothing wrong with the stock. When the selling is over, every great large cap stock will have gone down 20-30% through no fault of its' business plan or their earnings ratios. At that point, pfe will start a slow sustained rally. Look for the pain to be over in 2-4 weeks, but possibly sooner if the market cracks 7000 this week. Later, Br (still long pfe)

To: Sonki who wrote (5796)	10/5/1998 8:58:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 9523

Schering-Plough Sues Pfizer In Dispute Over Allergy Drug Settlement October 05, 1998 8:17 PM NEW YORK -(Dow Jones)- Schering-Plough Corp. filed a lawsuit Monday against Pfizer Inc., claiming the rival drug-maker broke a previous agreement that resolved a heated dispute between the two companies over their competing allergy drugs. Schering-Plough (SGP) markets Claritin, while Pfizer (PFE) markets the rival prescription allergy medication Zyrtec. The dispute between the two companies dates to 1996, when they attacked each other over their marketing practices - Schering-Plough claimed Pfizer salesmen were falsely touting their drug as nonsedating, while Pfizer claimed Schering-Plough salesmen put warning stickers on Zyrtec samples in doctors' offices. The two sides settled the litigation that resulted, promising to back off even though they didn't admit any wrongdoing. But in the new lawsuit, filed in federal court in New York, Schering-Plough alleged Pfizer has violated that settlement, by continuing to claim that Zyrtec doesn't cause drowsiness. That hurts Schering-Plough, the company says in its lawsuit, because if doctors and other medical professionals inaccurately think of Zyrtec as nonsedating, they're more likely to prescribe it instead of Claritin. The Food and Drug Administration has required Zyrtec to include a drowsiness warning in its labeling, because people who take it feel drowsy more often than might be expected from taking a placebo. Claritin is categorized as nonsedating and doesn't have to include such a warning. On Monday, Pfizer's (PFE) stock closed down $4.375, or 4.4%, to $94.75 a share, on New York Stock Exchange volume of about 5.5 million. Schering-Plough's (SGP) stock ended down 12.5 cents, or 0.13%, to $99.375 a share, on Big Board volume of 1.8 million. A spokeswoman for Pfizer said she wasn't aware of the new suit and had no immediate comment. UCB Pharma Inc., which also markets and sells Zyrtec, was also named as a defendant in the suit. UCB Pharma is a unit of Belgium's UCB S.A. Copyright (c) 1998 Dow Jones & Company, Inc. All Rights Reserved.